Pharmacogenomics in the pocket of every patient? A prototype based on quick response codes -- Samwald and Adlassnig. Journal of the American Medical Informatics Associationjamia.bmj.com doi:10.1136/amiajnl-2012-001275 Brief communication + Author Affiliations Correspondence to Dr Matthias Samwald, Section for Medical Expert and Knowledge-Based Systems, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Spitalgasse 23, BT 88.03, Vienna 1090, Austria; matthias.samwald@meduniwien.ac.at Received 18 August 2012 Revised 3 January 2013 Accepted 3 January 2013 Published Online First 23 January 2013 Abstract A sizable fraction of patients experiences adverse drug events or lack of drug efficacy.
A part of this variability in drug response can be explained by genetic differences between patients. Creating a future of personalized medicine: U-M forms joint venture for DNA diagnostics. Public release date: 16-Aug-2012 [ Print | E-mail Share ] [ Close Window ] Contact: Kara Gavinkegavin@umich.edu 734-764-2220University of Michigan Health System ANN ARBOR, Mich. and PHOENIX, Ariz. – As a key step toward providing patients with treatments based on their own DNA profiles, the University of Michigan and the International Genomics Consortium (IGC) have launched a new joint venture that will help usher in an age of personalized medicine. Called Paradigm, the new nonprofit company brings together the expertise of the U-M Health System and IGC, two leaders in using genetic information to understand and treat disease.
Beginning with cancer, and then extending into other disease groups, Paradigm will offer doctors and health care organizations anywhere access to whole gene and multi-gene sequencing and molecular diagnostics. The company will also help support clinical trials at UMHS and other health systems. About the U-M Health System About IGC [ Print | E-mail AAAS and EurekAlert!
Ion Torrent vies for $10 million genome prize. Nvidia Tesla GPUs to power EasyGenomics service for affordable DNA sequencing. Nvidia has teamed up with Chinese genomics institute BGI to create what's being described as an "affordable, cloud-based DNA sequencing service" called EasyGenomics. The service will feature a hybrid computing system that's powered by Nvidia's Tesla M2070 and M2075 GPUs, which can reportedly speed up the DNA analysis process from a few days to a few hours. The enhanced speed combined with BGI's sequencing platform (which just so happens to be the largest in the world) is expected to provide not only an easy to use platform, but also a relatively inexpensive one. "This could be the year of the $1,000 genome due to rapid decline in sequencing costs," Nvidia's Sumit Gupta explained. EasyGenomics will eventually expand the system with hundreds of Tesla GPUs, and when the service is fully deployed it's expected to support thousands of users with automated DNA sequence analysis — including biologists, bioinformaticists and, physicians.
Personalized medicine market in growth mode. Led by tissue tests to aid drug therapy decisions, the personalized medicine testing market exceeded $28 billion in 2011, according to Kalorama Information. The healthcare market research publisher includes in its analysis all tests that are used to determine the appropriate therapeutic on an individual patient.
[See also: GE makes investment in NanoString Technologies] This broad scope includes new molecular tests based on proven biomarkers, as well as routine glucose and microbial identification tests. The dynamic part of the market is the new tests, and according to Kalorama's report, "World Market for Personalized Medicine Diagnostics," the tests that have turned personalized medicine from concept to reality are tissue tests that determine therapy for cancer. These will experience better than average IVD industry revenue growth rates in the next five years. [See also: Dell launches cloud technology platform, targeting treatment for pediatric cancer] Group Set To Sequence 1000 Genomes By The End Of The Year. Begun in 2008, the "1000 Genomes Project" aims to sequence 1000 genomes and gain a deeper understanding of what genetic variations may put people at risk for disease.
When the Human Genome Project got underway in 1990 it was expected to take 15 years to sequence the over 3 billion chemical base pairs that spell out our genetic code. In true Moore’s Law tradition the emergence of faster and more efficient sequencing technologies along the way led to the Project’s early completion in 2003. Today, 22 years after scientists first committed to the audacious goal of sequencing the genome, the next generation of sequencers are setting their sites much higher. About a thousand times higher. The 1000 Genomes Project, as its name suggests, is a joint public-private effort to sequence 1000 genomes. Begun in 2008, the Project’s main goal is to create an “extensive catalog of human genetic variation that will support future medical research studies.” That might not sound like much. USB stick can sequence DNA in seconds - 17 February 2012. By Duncan Graham-Rowe It may look like an ordinary USB memory stick, but a little gadget that can sequence DNA while plugged into your laptop could have far-reaching effects on medicine and genetic research.
The UK firm Oxford Nanopore built the device, called MinION, and claims it can sequence simple genomes – like those of some viruses and bacteria – in a matter of seconds. More complex genomes would take longer, but MinION could also be useful for obtaining quick results in sequencing DNA from cells in a biopsy to look for cancer, for example, or to determine the genetic identity of bone fragments at an archaeological dig. The company demonstrated today at the Advances in Genome Biology and Technology (AGBT) conference in Marco Island, Florida, that MinION has sequenced a simple virus called Phi X, which contains 5000 genetic base pairs. Proof of principle Oxford Nanopore is also building a larger device, GridION, for lab use. Long strands, and simple Pocketful of DNA More on these topics: Preparing for Precision Medicine.